P A Bird1, A G Hill, N Houssami. 1. Africa Inland Church (AIC) Kijabe Hospital, Kijabe, Kenya. bird@kijabe.net
Abstract
BACKGROUND: Few studies have examined breast cancer hormone receptor expression in Africans. We report on the hormone receptor profile of breast cancer in East Africans in the largest prospective study for this region. METHODS: Consecutive breast cancer presentations to a hospital in Kijabe (2001-2007) were included. Demographic, clinical, and test data were collected. ER/PR and Her2 testing was based on immunohistochemistry (IHC). RESULTS: There were 129 subjects (median 47 years), most had invasive ductal cancer and locally advanced disease and/or metastases. ER/PR testing was done in 120: 24% had ER-positive tumours, 34% were ER- and/or PR-positive, 10% were ER-negative but PR-positive tumours, and 66% were negative for ER and PR. ER/PR positivity was not associated with stage (P = 0.28) and was not related to age, parity, menopausal status, or node metastases. Increasing tumour grade was associated with PR expression (P = 0.02) with decreasing frequency of PR positive tumours as histological grade increased; there was weak evidence of an association between grade and ER expression (P = 0.06). Of cases tested, 26.5% overexpressed Her2. CONCLUSIONS: Breast cancer in Kijabe is an advanced-stage disease, comprised mainly of poorly differentiated cancers that are less likely to be hormone sensitive (across all stages of disease). ER/PR testing of all those affected by breast cancer should be supported as a global priority in cancer control. International and inter-African research collaborations are needed to allow genetic detailing of tumours in indigenous Africans to assess possible racial heterogeneity in the biology of breast cancer.
BACKGROUND: Few studies have examined breast cancerhormone receptor expression in Africans. We report on the hormone receptor profile of breast cancer in East Africans in the largest prospective study for this region. METHODS: Consecutive breast cancer presentations to a hospital in Kijabe (2001-2007) were included. Demographic, clinical, and test data were collected. ER/PR and Her2 testing was based on immunohistochemistry (IHC). RESULTS: There were 129 subjects (median 47 years), most had invasive ductal cancer and locally advanced disease and/or metastases. ER/PR testing was done in 120: 24% had ER-positive tumours, 34% were ER- and/or PR-positive, 10% were ER-negative but PR-positive tumours, and 66% were negative for ER and PR. ER/PR positivity was not associated with stage (P = 0.28) and was not related to age, parity, menopausal status, or node metastases. Increasing tumour grade was associated with PR expression (P = 0.02) with decreasing frequency of PR positive tumours as histological grade increased; there was weak evidence of an association between grade and ER expression (P = 0.06). Of cases tested, 26.5% overexpressed Her2. CONCLUSIONS:Breast cancer in Kijabe is an advanced-stage disease, comprised mainly of poorly differentiated cancers that are less likely to be hormone sensitive (across all stages of disease). ER/PR testing of all those affected by breast cancer should be supported as a global priority in cancer control. International and inter-African research collaborations are needed to allow genetic detailing of tumours in indigenous Africans to assess possible racial heterogeneity in the biology of breast cancer.
Authors: Shahin Sayed; Zahir Moloo; Ronald Wasike; Peter Bird; Raymond Oigara; Faith Wambui Njoroge; Asim Jamal Shaikh; Satya Vara Prasad; Sudhir Vinayak; Gretchen L Gierach; Sanford M Dawsey; Maya Palakal; Shaoqi Fan; Maeve Mullooly; Rajendra Chauhan; Patricia Okiro; Samuel Gakinya; Ancent Nzioka; Catherine Kyobutungi; Shukri Mohamed; Tilahun Haregu; Mustafa Mussajee; Betty Bonass; Costa Mariwa; Omar Ali Sherman; Abdihakim Mohammed; Andrew Gachii; Joseph Githaiga; Joseph Karanu; Robert Nyagah; Richard Njoroge; Irene Muramba; James Obondi Otieno; Dan Omondi Raburu; Elizabeth B Mwachiro; Innocent Abayo; Mansoor Saleh Journal: Breast Cancer Res Treat Date: 2017-09-26 Impact factor: 4.872
Authors: Azadeh Stark; Celina G Kleer; Iman Martin; Baffour Awuah; Anthony Nsiah-Asare; Valerie Takyi; Maria Braman; Solomon E Quayson; Richard Zarbo; Max Wicha; Lisa Newman Journal: Cancer Date: 2010-11-01 Impact factor: 6.860
Authors: Louise A Brinton; Jonine D Figueroa; Baffour Awuah; Joel Yarney; Seth Wiafe; Shannon N Wood; Daniel Ansong; Kofi Nyarko; Beatrice Wiafe-Addai; Joe Nat Clegg-Lamptey Journal: Breast Cancer Res Treat Date: 2014-03-07 Impact factor: 4.872
Authors: Theresa Schwartz; Azadeh Stark; Judy Pang; Baffour Awuah; Celina G Kleer; Solomon Quayson; Stephanie Kingman; Francis Aitpillah; Francis Abantanga; Evelyn Jiagge; Joseph K Oppong; Ernest Osei-Bonsu; Iman Martin; Xiaowei Yan; Kathy Toy; Ernest Adjei; Max Wicha; Lisa A Newman Journal: Cancer Date: 2012-08-28 Impact factor: 6.860
Authors: Mandeep Singh; Yi Ding; Li-Ying Zhang; Dong Song; Yun Gong; Sylvia Adams; Dara S Ross; Jin-Hua Wang; Shruti Grover; Dinesh Chandra Doval; Charles Shao; Zi-Li He; Victor Chang; Warren W Chin; Fang-Ming Deng; Baljit Singh; David Zhang; Ru-Liang Xu; Peng Lee Journal: Am J Cancer Res Date: 2014-07-16 Impact factor: 6.166